In vitro activity of human chorionic gonadotropin (hCG) on myometrium contractility

Angioni, Stefano; Spedicato, Massimo; Rizzo, Annalisa; Cosola, Claudia; Mutinati, Maddalena; Minoia, Giuseppe; Sciorsci, Raffaele Luigi

doi:10.3109/09513590.2010.488780

Cited by 10 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rao and colleagues showed the capability of hCG to inhibit prostaglandin-induced preterm delivery in a murine model [87]. Recent physiological evidence has shown a dose dependent decrease in myometrial contractility with increasing doses of hCG [88]. However clinical trials have not yet been able to demonstrate any significant decrease in miscarriage rates upon hCG administration and many of these postulated functions remain to be independently validated in appropriate and well-designed clinical trials [89–91].…”

Section: Diagnostic and Therapeutic Applications Of Hcgmentioning

confidence: 99%

Extragonadal actions of chorionic gonadotropin

Banerjee

Fazleabas

2011

Rev Endocr Metab Disord

View full text Add to dashboard Cite

The primary embryonic signal in primates is chorionic gonadotropin (CG, designated hCG in humans), that is classically associated with corpus luteum rescue and progesterone production. However, research over the past decade has revealed the presence of the hCG receptor in a variety of extragonadal tissues. Additionally, discoveries of the multiple variants of hCG, namely, native hCG, hyperglycosylated hCG (hyp-hCG) and the β-subunit of the hyperglycosylated hCG (hCG-free β) has established a role for extragonadal actions of hCG. For the initiation and maintenance of pregnancy, hCG mediates multiple placental, uterine and fetal functions. Some of these include development of syncytiotrophoblast cells, mitotic growth and differentiation of the endometrium, localized suppression of the maternal immune system, modulation of uterine morphology and gene expression and coordination of intricate signal transduction between the endometrium. Recurrent pregnancy loss, preeclampsia and endometriosis are associated with altered responses of hCG, all of which have a detrimental effect on pregnancy. A role for hyp-hCG in mediating the development of both trophoblastic and non-trophoblastic tumors has also been suggested. Other significant non-gonadal applications of hCG include predicting preeclampsia, determining the risk of Down’s syndrome and gestational trophoblastic disease, along with relaxing myometrial contractility and preventing recurrent miscarriages. Presence of hCG free-β in serum of cancer patients enables its usage as a diagnostic tumor marker. Thus, the extragonadal functions of hCG encompasses a wide spectrum of applications and is an open area for continued investigation.

show abstract

Section: Diagnostic and Therapeutic Applications Of Hcgmentioning

confidence: 99%

Extragonadal actions of chorionic gonadotropin

Banerjee

Fazleabas

2011

Rev Endocr Metab Disord

View full text Add to dashboard Cite

show abstract

“…Finally, it is interesting to point out that myometrial hCG/LH receptors are also present in animals and their activation results in an inhibition of contractions amplitude, just as in human myometrium. 41,42 Table 1 lists all the actions of hCG in myometrium.…”

Section: The Hcg Receptors In Human Myometriummentioning

confidence: 99%

Why are We Waiting to Start Large Scale Clinical Testing of Human Chorionic Gonadotropin for the Treatment of Preterm Births?

Rao

2016

Reprod. Sci.

View full text Add to dashboard Cite

Preterm births are an expensive global health problem. Despite the basic science and clinical research advances to better understand and prevent preterm births, the rates are increasing. There are several therapeutic options. While some options such as progestins work for selected women, others such as magnesium sulfate can only be used for delaying births for 24 to 48 hours so that the patients can be treated with corticosteroids to promote fetal lung maturity. Based on the scientific and clinical evidence, we recommend testing human chorionic gonadotropin in a large multicenter, randomized, double-blind, and placebo-controlled clinical trials in women with active preterm labor and those with a previous history of preterm births. Human chorionic gonadotropin is not only inexpensive but also has not shown any side effects so far in the infants or in the mothers.

show abstract

“…Besides detrusor muscle, hCG can inhibit the contractions of myometrial smooth muscle and vascular smooth muscle in reproductive organs, which explains the minimal side effects. [45][46][47][48][68][69][70][71][72][73][74][75][76][77][78][79][80][81] There are still many unanswered scientific questions with regard to hCG in OAB. Some of the answers come from clinical trials and others from continued hCG research on bladder.…”

Section: Why Does the Hcg Therapy Merits Considerationmentioning

confidence: 99%

Therapeutic Potential of Human Chorionic Gonadotropin Against Overactive Bladder

Rao

2016

Reprod. Sci.

View full text Add to dashboard Cite

Overactive bladder (OAB) is a common form of urinary incontinence, resulting from spontaneous and random contractions of the urinary bladder. The affected individuals have an uncontrollable urge to urinate and experience incontinence and nocturia, which can greatly reduce the quality of daily life. There are several drugs for the treatment, and all of them have serious side effects. The following findings suggested that human chorionic gonadotropin (hCG) has a therapeutic potential that is worth investigating for the treatment of OAB. The finding are (1) human detrusor muscle contains hCG receptors, (2) detrusor muscle becomes quiescent during pregnancy, (3) hCG can inhibit detrusor muscle contractions induced by cholinergic stimulation in rats, and (4) hCG can mimic the anticholinergic drug on detrusor muscle contractions.

show abstract

In vitro activity of human chorionic gonadotropin (hCG) on myometrium contractility

Cited by 10 publications

References 29 publications

Extragonadal actions of chorionic gonadotropin

Extragonadal actions of chorionic gonadotropin

Why are We Waiting to Start Large Scale Clinical Testing of Human Chorionic Gonadotropin for the Treatment of Preterm Births?

Therapeutic Potential of Human Chorionic Gonadotropin Against Overactive Bladder

Contact Info

Product

Resources

About